Upcoming Dividend • May 13
Upcoming dividend of €0.12 per share Eligible shareholders must have bought the stock before 20 May 2026. Payment date: 22 May 2026. The company is paying out more than 100% of its profits but is generating plenty of cash to support the dividend. Trailing yield: 0.7%. Lower than top quartile of British dividend payers (5.8%). Lower than average of industry peers (4.0%). Reported Earnings • Apr 08
Full year 2025 earnings released Full year 2025 results: Revenue: €47.0m (down 10.0% from FY 2024). Net income: €5.7k (up €5.31m from FY 2024). Profit margin: 0% (up from net loss in FY 2024). The move to profitability was driven by lower expenses. Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 7.0% decline forecast for the Chemicals industry in the United Kingdom. New Risk • Mar 20
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €2.8m Forecast net loss in 2 years: €209k This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Currently unprofitable and not forecast to become profitable over next 2 years (€209k net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). Market cap is less than US$100m (€84.8m market cap, or US$98.2m). New Risk • Mar 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). New Risk • Feb 11
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €82.4m (US$97.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (9.7% average weekly change). Market cap is less than US$100m (€82.4m market cap, or US$97.9m). New Risk • Jan 01
New minor risk - Profitability The company is currently unprofitable and not forecast to become profitable over the next 2 years. Trailing 12-month net loss: €2.8m Forecast net loss in 2 years: €1.3m This is considered a minor risk. Companies that are not profitable are more likely to be burning through cash and less likely to be well established. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. Without profits, the company is under pressure to grow significantly while potentially having to reduce costs and possibly needing to take on debt or raise capital to remain afloat. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (27% average weekly change). Minor Risk Currently unprofitable and not forecast to become profitable over next 2 years (€1.3m net loss in 2 years). Duyuru • Jun 24
IBU-tec advanced materials AG to Report First Half, 2025 Results on Aug 27, 2025 IBU-tec advanced materials AG announced that they will report first half, 2025 results on Aug 27, 2025 Reported Earnings • May 19
Full year 2024 earnings released Full year 2024 results: Revenue: €54.1m (up 10% from FY 2023). Net loss: €5.31m (loss widened 113% from FY 2023). Revenue is forecast to grow 11% p.a. on average during the next 2 years, compared to a 4.6% decline forecast for the Chemicals industry in the United Kingdom. Duyuru • Apr 17
IBU-tec advanced materials AG, Annual General Meeting, May 26, 2025 IBU-tec advanced materials AG, Annual General Meeting, May 26, 2025, at 10:00 W. Europe Standard Time. Duyuru • Apr 16
Ibu-Tec Advanced Materials Ag Provides Revenue Guidance for 2025 Ibu-Tec Advanced Materials Ag provided Revenue Guidance for 2025. For the period, the company expected revenue EUR 43 million to EUR 45 million after consolidated revenues of around EUR 50.6 million in the past financial year according to preliminary unaudited figures. New Risk • Mar 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Market cap is less than US$100m (€28.3m market cap, or US$30.8m). Duyuru • Jan 08
IBU-tec advanced materials AG to Report Fiscal Year 2024 Results on Mar 20, 2025 IBU-tec advanced materials AG announced that they will report fiscal year 2024 results at 12:00 PM, Central European Standard Time on Mar 20, 2025 Reported Earnings • Sep 01
First half 2024 earnings released: €0.66 loss per share (vs €0.078 profit in 1H 2023) First half 2024 results: €0.66 loss per share (down from €0.078 profit in 1H 2023). Revenue: €25.3m (down 1.1% from 1H 2023). Net loss: €3.15m (down €3.53m from profit in 1H 2023). Revenue is forecast to grow 22% p.a. on average during the next 3 years, compared to a 5.7% decline forecast for the Chemicals industry in the United Kingdom. Duyuru • Aug 29
IBU-tec advanced materials AG to Report First Half, 2024 Results on Aug 27, 2024 IBU-tec advanced materials AG announced that they will report first half, 2024 results on Aug 27, 2024 Duyuru • Mar 22
IBU-tec advanced materials AG, Annual General Meeting, Apr 30, 2024 IBU-tec advanced materials AG, Annual General Meeting, Apr 30, 2024. Valuation Update With 7 Day Price Move • Mar 22
Investor sentiment improves as stock rises 35% After last week's 35% share price gain to €12.68, the stock trades at a trailing P/E ratio of 51.8x. Average trailing P/E is 20x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 61% over the past year. Duyuru • Mar 21
IBU-tec advanced materials AG to Report Fiscal Year 2023 Results on Mar 21, 2024 IBU-tec advanced materials AG announced that they will report fiscal year 2023 results on Mar 21, 2024 New Risk • Mar 12
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). High level of non-cash earnings (22% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Market cap is less than US$100m (€47.5m market cap, or US$51.9m). Valuation Update With 7 Day Price Move • Mar 07
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €9.99, the stock trades at a trailing P/E ratio of 41.5x. Average trailing P/E is 17x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 71% over the past year. Valuation Update With 7 Day Price Move • Feb 06
Investor sentiment deteriorates as stock falls 18% After last week's 18% share price decline to €13.12, the stock trades at a trailing P/E ratio of 54.9x. Average trailing P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 60% over the past year. Valuation Update With 7 Day Price Move • Jan 15
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to €13.22, the stock trades at a trailing P/E ratio of 48.1x. Average forward P/E is 18x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 63% over the past year. New Risk • Dec 09
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €90.7m (US$97.7m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (22% accrual ratio). Minor Risk Market cap is less than US$100m (€90.7m market cap, or US$97.7m). Valuation Update With 7 Day Price Move • Oct 23
Investor sentiment deteriorates as stock falls 20% After last week's 20% share price decline to €18.54, the stock trades at a forward P/E ratio of 57x. Average forward P/E is 15x in the Chemicals industry in the United Kingdom. Total returns to shareholders of 9.8% over the past year. New Risk • Oct 21
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: €92.1m (US$97.5m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (22% accrual ratio). Minor Risk Market cap is less than US$100m (€92.1m market cap, or US$97.5m). Reported Earnings • Aug 30
First half 2023 earnings released: EPS: €0.078 (vs €0.10 in 1H 2022) First half 2023 results: EPS: €0.078 (down from €0.10 in 1H 2022). Revenue: €25.5m (down 14% from 1H 2022). Net income: €372.8k (down 24% from 1H 2022). Profit margin: 1.5% (down from 1.7% in 1H 2022). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 5.0% decline forecast for the Chemicals industry in the United Kingdom. New Risk • Aug 28
New major risk - Earnings quality The company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. High level of non-cash earnings (22% accrual ratio).